Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briciclib in advanced solid tumors
NCT02168725Phase 1Terminated
- Sponsor
- Traws Pharma, Inc.
- Start
- Jun 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bireociclib in solid tumor (advanced stage), sponsored by Traws Pharma, Inc. Primary endpoints: Number of patients with adverse events up to 1 year, Number of patients with Dose Limiting Toxicity up to 3 weeks and 1 more. Started Jun 2014; status: terminated.
02
Drugs
bireociclib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02168725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168725.